Table 1.
Comparison of clinicopathologic features between TD-absent and TD-present gastric cancer patients before and after PSM
| Variables | Before PSM | After PSM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TD-absent | TD-present | P value | SMD | TD-absent | TD-present | P value | SMD | |||||
| n | % | n | % | n | % | n | % | |||||
| Overall | 1714 | 201 | 491 | 191 | ||||||||
| Sex | ||||||||||||
| Male | 1184 | 69.1 | 149 | 74.1 | 0.164 | 0.112 | 355 | 72.3 | 140 | 73.3 | 0.868 | 0.022 |
| Female | 530 | 30.9 | 52 | 25.9 | 136 | 27.7 | 51 | 26.7 | ||||
| Age (years) | ||||||||||||
| < 58 | 917 | 53.5 | 78 | 38.8 | < 0.001 | 0.298 | 205 | 41.8 | 77 | 40.3 | 0.798 | 0.029 |
| ≥ 58 | 797 | 46.5 | 123 | 61.2 | 286 | 58.2 | 114 | 59.7 | ||||
| Mean (SD) | 56.9 ± 11.1 | 61.0 ± 10.6 | 59.9 ± 10.6 | 60.7 ± 10.6 | ||||||||
| Median (range) | 58 (19–82) | 62 (33–84) | 61 (28–82) | 62 (33–84) | ||||||||
| Tumor location | ||||||||||||
| GEJ + Upper 1/3 | 431 | 25.1 | 68 | 33.8 | 0.013 | 0.217 | 163 | 33.2 | 65 | 34.0 | 0.964 | 0.023 |
| Middle 1/3 | 417 | 24.3 | 51 | 25.4 | 122 | 24.8 | 48 | 25.1 | ||||
| Lower 1/3 | 866 | 50.5 | 82 | 40.8 | 206 | 42.0 | 78 | 40.8 | ||||
| Tumor size | ||||||||||||
| <3.2 cm | 922 | 53.8 | 45 | 22.4 | < 0.001 | 0.683 | 145 | 29.5 | 45 | 23.6 | 0.142 | 0.136 |
| ≥ 3.2 cm | 792 | 46.2 | 156 | 77.6 | 346 | 70.5 | 146 | 76.4 | ||||
| Mean (SD) | 3.6 ± 2.1 | 5.1 ± 2.3 | 4.7 ± 2.3 | 4.9 ± 2.1 | ||||||||
| Median (range) | 3.0 (0.3–16.0) | 4.5 (0.8–14.0) | 4.5 (0.5–14) | 6.0 (0.8–12) | ||||||||
| Histologic grade | ||||||||||||
| Well-moderately | 325 | 19.0 | 29 | 14.4 | 0.141 | 0.122 | 68 | 13.8 | 28 | 14.7 | 0.880 | 0.023 |
| Poorly | 1389 | 81.0 | 172 | 85.6 | 423 | 86.2 | 163 | 85.3 | ||||
| T category | ||||||||||||
| T1 | 521 | 30.4 | 2 | 1.0 | < 0.001 | 1.131 | 6 | 1.2 | 2 | 1.0 | 0.508 | 0.148 |
| T2 | 255 | 14.9 | 11 | 5.5 | 35 | 7.1 | 11 | 5.8 | ||||
| T3 | 187 | 10.9 | 14 | 7.0 | 42 | 8.6 | 14 | 7.3 | ||||
| T4a | 731 | 42.6 | 158 | 78.6 | 393 | 80.0 | 153 | 80.1 | ||||
| T4b | 20 | 1.2 | 16 | 8.0 | 15 | 3.1 | 11 | 5.8 | ||||
| N category | ||||||||||||
| N0 | 790 | 46.1 | 16 | 8.0 | < 0.001 | 1.023 | 50 | 10.2 | 16 | 8.4 | 0.846 | 0.100 |
| N1 | 308 | 18.0 | 36 | 17.9 | 97 | 19.8 | 36 | 18.8 | ||||
| N2 | 280 | 16.3 | 50 | 24.9 | 132 | 26.9 | 49 | 25.7 | ||||
| N3a | 259 | 15.1 | 74 | 36.8 | 164 | 33.4 | 67 | 35.1 | ||||
| N3b | 77 | 4.5 | 25 | 12.4 | ||||||||
| TNM stage | ||||||||||||
| I | 620 | 36.2 | 3 | 1.5 | < 0.001 | 1.209 | 16 | 3.3 | 3 | 1.6 | 0.365 | 0.128 |
| II | 398 | 23.2 | 22 | 10.9 | 66 | 13.4 | 22 | 11.5 | ||||
| III | 696 | 40.6 | 176 | 87.6 | 409 | 83.3 | 166 | 86.9 | ||||
| VELIPI | ||||||||||||
| Negative | 996 | 58.1 | 54 | 26.9 | < 0.001 | 0.666 | 147 | 29.9 | 54 | 28.3 | 0.738 | 0.037 |
| Positive | 718 | 41.9 | 147 | 73.1 | 344 | 70.1 | 137 | 71.7 | ||||
| No. of retrieved LNs | ||||||||||||
| < 15 | 331 | 19.3 | 36 | 17.9 | 0.702 | 0.036 | 86 | 17.5 | 33 | 17.3 | 1.000 | 0.006 |
| ≥ 15 | 1383 | 80.7 | 165 | 82.1 | 405 | 82.5 | 158 | 82.7 | ||||
| Mean (SD) | 21.3 ± 8.4 | 21.9 ± 8.4 | 21.9 ± 8.3 | 22.0 ± 8.5 | ||||||||
| Median (range) | 20 (2–74) | 20 (8–62) | 20 (5–55) | 20 (8–62) | ||||||||
| Adjuvant treatment | ||||||||||||
| No | 501 | 29.2 | 38 | 18.9 | < 0.001 | 0.388 | 66 | 13.4 | 32 | 16.8 | 0.812 | 0.106 |
| Single drug | 304 | 17.7 | 40 | 19.9 | 104 | 21.2 | 38 | 19.9 | ||||
| Double drugs | 625 | 36.5 | 63 | 31.3 | 177 | 36.0 | 63 | 33.0 | ||||
| Triple drugs | 167 | 9.7 | 43 | 21.4 | 101 | 20.6 | 41 | 21.5 | ||||
| CRT | 117 | 6.8 | 17 | 8.5 | 43 | 8.8 | 17 | 8.9 | ||||
Abbreviations: CI confidence interval, GEJ gastroesophageal junction, LNs lymph nodes, PSM propensity score matching, SD standard difference, SMD standardized mean difference, TD tumor deposit, VELIPI vascular emboli, lymphatic, and perineural invasion